Peter E. Zage MD Ph.D.

Pediatric Hematology & Oncology•San Diego, CA

Pediatric Solid Tumor Oncology

Associate Professor in Residence, Pediatric Hematology & Oncology, University of California San Diego

Join to View Full Profile

3010 Childrens Way 2 WestSan Diego, CA 92123
Phone+1 858-966-5811

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Pediatric Hematology/Oncology, 2002 - 2005
University of ChicagoResidency, Pediatrics, 1999 - 2002
Columbia University Vagelos College of Physicians and SurgeonsClass of 1999

Certifications & Licensure

CA State Medical License 2016 - 2025
TX State Medical License 2005 - 2025
IL State Medical License 1999 - 2017
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement Start of enrollment: 2005 Apr 01
Completed
Phase 1
Doxercalciferol in Recurrent Pediatric Solid Tumors Start of enrollment: 2007 Aug 01
Terminated
Phase 1
ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma Start of enrollment: 2007 Sep 01
Terminated
Phase 1
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Start of enrollment: 2008 Jan 14
COMPLETED
PHASE2
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2009 Dec 01
Completed
Phase 1
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
RECRUITING
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Start of enrollment: 2010 Mar 01
Completed
Phase 1
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma Start of enrollment: 2010 Dec 01
Completed
Phase 1
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma Start of enrollment: 2011 Dec 01
Completed
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission Start of enrollment: 2012 Jun 01
Active, not recruiting
Phase 2
Molecular-Guided Therapy for Childhood Cancer Start of enrollment: 2014 Jul 08
COMPLETED
NA
Neuroblastoma Maintenance Therapy Trial
RECRUITING
PHASE2
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors Start of enrollment: 2018 Aug 28
RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

Multimodal cell maps as a foundation for structural and functional genomics.
Leah V Schaffer, Mengzhou Hu, Gege Qian, Kyung-Mee Moon, Abantika Pal
Nature. 2025-04-09
3 citations
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Rochelle Bagatell, Julie R Park, Sahaja Acharya, Jennifer Aldrink, Jenna Allison
Journal of the National Comprehensive Cancer Network. 2024-08-01
13 citations
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Javier Oesterheld, William Ferguson, Jacqueline M Kraveka, Genevieve Bergendahl, Thomas Clinch
Journal of Clinical Oncology. 2024-01-01

Press Mentions

Loss of the PTCH1 Tumor Suppressor Defines a New Subset of Plexiform FibromyxomaJuly 30th, 2019

Peter E. Zage MD Ph.D.

Dr. Zage is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.